Artal Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

Artal Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-67,909	Closed	-$566K	–	123
2023 Q1	$566K	Buy	+67,909	New	+$654K	0.03%	100
2018 Q1	–	Sell	-500,000	Closed	-$2.46M	–	114
2017 Q4	$2.46M	Sell	500,000 -150,000	-23%	-$727K	0.04%	91
2017 Q3	$3.41M	Sell	650,000 -200,000	-24%	-$1.02M	0.06%	78
2017 Q2	$4.73M	Buy	850,000 +350,000	+70%	+$2.13M	0.08%	65
2017 Q1	$4.2M	Buy	+500,000	New	+$3.48M	0.09%	66

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Artal Group's BCRX Position: Q2 2023 in Review

Artal Group sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2023, closing a stake of 67,909 shares — an estimated $566K sold.

Artal Group first reported a position in BCRX in Q1 2017 and held it in 5 quarters. The position peaked at $4.73M in Q2 2017. 236 funds tracked by Wall St. Rank hold BCRX as of Q2 2023.

Artal Group reported no remaining BioCryst Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Artal Group sold 67,909 BioCryst Pharmaceuticals shares in Q2 2023, an estimated $566K.
Artal Group first reported a position in BioCryst Pharmaceuticals in Q1 2017 and held it in 5 quarters.
Artal Group's BioCryst Pharmaceuticals position peaked at $4.73M in Q2 2017.
236 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.